Difference between revisions of "Tivozanib (Fotivda)"
Jump to navigation
Jump to search
m |
m |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=561728 NCI Drug Dictionary]: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.<ref name="insert">[https://www.fotivdahcp.com/fotivdapi.pdf Tivozanib (Fotivda) package insert]</ref><ref>[[:File:Tivozanib.pdf | Tivozanib (Fotivda) package insert (locally hosted backup)]]</ref><ref>[https://www.fotivda.com/ Fotivda manufacturer's website]</ref> | From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=561728 NCI Drug Dictionary]: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.<ref name="insert">[https://www.fotivdahcp.com/fotivdapi.pdf Tivozanib (Fotivda) package insert]</ref><ref>[[:File:Tivozanib.pdf | Tivozanib (Fotivda) package insert (locally hosted backup)]]</ref><ref>[https://www.fotivda.com/ Fotivda manufacturer's website]</ref> | ||
| − | ==Diseases for which it is established | + | ==Diseases for which it is established== |
*[[Renal cell carcinoma]] | *[[Renal cell carcinoma]] | ||
| + | **[[Clear cell renal cell carcinoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 10: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2021-03-10: Approved for adult patients with relapsed or refractory advanced [[renal cell carcinoma|renal cell carcinoma (RCC)]] following two or more prior systemic therapies. ''(Based on TIVO-3)'' |
| + | ==History of changes in EMA indication== | ||
| + | *2017-08-24: Initial authorization for first line treatment of adult patients with advanced [[renal cell carcinoma|renal cell carcinoma (RCC)]]. ''(Based on TIVO-1)'' | ||
| + | *2017-08-24: Initial authorization for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced [[renal cell carcinoma|RCC]]. ''(Based on TIVO-1)'' | ||
==Also known as== | ==Also known as== | ||
| Line 24: | Line 28: | ||
[[Category:VEGFR inhibitors]] | [[Category:VEGFR inhibitors]] | ||
| + | [[Category:Clear cell renal cell carcinoma medications]] | ||
[[Category:Renal cell carcinoma medications]] | [[Category:Renal cell carcinoma medications]] | ||
| − | [[Category:EMA approved | + | [[Category:EMA approved in 2017]] |
[[Category:FDA approved in 2021]] | [[Category:FDA approved in 2021]] | ||
Revision as of 00:29, 7 November 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.[1][2][3]
Diseases for which it is established
Patient drug information
History of changes in FDA indication
- 2021-03-10: Approved for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. (Based on TIVO-3)
History of changes in EMA indication
- 2017-08-24: Initial authorization for first line treatment of adult patients with advanced renal cell carcinoma (RCC). (Based on TIVO-1)
- 2017-08-24: Initial authorization for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. (Based on TIVO-1)
Also known as
- Code name: AV-951
- Brand name: Fotivda